Burt Adelman. Novo Ventures
November 19, 2019 09:36 AM ESTUpdated November 20, 07:22 AM
Financing
Discovery

Here's a $25M seed fund aimed at back­ing some brash new drug ideas out of the Broad

Amber Tong

As a for­mer aca­d­e­m­ic and a sea­soned drug de­vel­op­er, Burt Adel­man knew when he was re­cruit­ed as a se­nior ad­vi­sor to No­vo Ven­tures in 2017 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times